Interested in taking your stroke program to the next level?
Please join us for a webinar
Quality and Metrics: Assessing and Improving the Quality of Stroke Care
April 12, 2017
12 PM ET/9 AM PT
3 PM ET/12 PM PT
Click here to register >https://idmeetings.com/Intramed/8230B.nsf/Register?Open&Subform=Main&c=MMATAIACTWBNR95&moc=MMATAIACTWBNR95&cid=acv_EM_MMATAIACTWBNR95_1
Program Objectives:
•
Discuss the importance of capturing quality metrics and instituting quality improvement programs
•
Describe why tracking All-AIS treatment rate can provide a broader assessment of your stroke program
•
Consider different ways to optimize stroke processes and assess for missed eligible patients
•
Discuss simple and effective methods to communicate program insights to your team
Audience
Intended audience: Quality Directors, Stroke Coordinators, ED Nurses, Neurology Nurses, Stroke Neurologist, ED Director
Presented by
Peter D. Panagos, MD, FACEP, FAHA Associate Professor, Emergency Medicine & Neurology
Washington University School of Medicine
St. Louis, Missouri
Peter D. Panagos, MD, FACEP, FAHA Associate Professor, Emergency Medicine & Neurology
*Speakers have been compensated by Genentech for their participation.
If you have any questions regarding this webinar, please contact your local Genentech representative.
Note: No CEUs will be offered for attending this session.
Indication
Activase (alteplase) is indicated for the treatment of acute ischemic stroke. Exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment. Initiate treatment as soon as possible but within 3 hours after symptom onset.
Important Safety Information
Contraindications
Do not administer Activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit: current intracranial hemorrhage (ICH); subarachnoid hemorrhage; active internal bleeding; recent (within 3 months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding; bleeding diathesis; and current severe uncontrolled hypertension.
Warnings and Precautions
Bleeding
Activase can cause significant, sometimes fatal, internal or external bleeding, especially at arterial and venous puncture sites. Avoid intramuscular injections and trauma to the patient. Fatal cases of hemorrhage associated with traumatic intubation in patients administered Activase have been reported. Heparin, aspirin, or Activase may cause bleeding complications; therefore carefully monitor for bleeding. If serious bleeding occurs, terminate the Activase infusion.
Orolingual Angioedema
Monitor patients during and for several hours after infusion for orolingual angioedema. If angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy.
Cholesterol Embolization
Cholesterol embolism, sometimes fatal, has been reported rarely in patients treated with thrombolytic agents.
Coagulation Tests May be Unreliable during Activase Therapy
Coagulation tests and/or measures of fibrinolytic activity may be unreliable during Activase therapy.
Adverse Reactions
The most frequent adverse reaction associated with Activase AIS therapy is bleeding.
Allergic type reactions, e.g., anaphylactoid reaction, laryngeal edema, orolingual angioedema, rash, and urticaria have been reported.
Please see full Prescribing Information for additional Important Safety Information.
Visit Activase.com for more information and resources.
Genentech
Privacy Policy | Terms and Conditions | Contact Genentech®
This email is intended for US healthcare professionals only.
This email is intended for the recipient identified above. If you have received this email in error, please notify the sender immediately and delete the email from your system.
To unsubscribe from this type of informational email as delivered by your Genentech representative, please click here. Regular communications between you and your Genentech representative regarding standard business and meeting coordination activities may continue.
This promotional email is brought to you by Genentech.
© 2017 Genentech USA, Inc. All rights reserved.
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990
ACI/021317/0002
ACI/021317/0002a